CVS 2589

Drug Profile

CVS 2589

Alternative Names: CVS2589

Latest Information Update: 12 Sep 2002

Price : $50

At a glance

  • Originator Dendreon San Diego LLC
  • Class Antithrombotics
  • Mechanism of Action Plasminogen activator inhibitors; Urokinase-type plasminogen activator inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer; Diabetic retinopathy

Most Recent Events

  • 12 Sep 2002 Discontinued - Preclinical for Cancer in USA (unspecified route)
  • 12 Sep 2002 Discontinued - Preclinical for Diabetic retinopathy in USA (unspecified route)
  • 07 Apr 1999 Preclinical development for Diabetic retinopathy in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top